Here's my view on this space and where the money is to be made.
Getting international travel and commerce back on track may hinge on vaccine acceptance.
The market's mood seems to be changing almost daily; he's an approach for how to trade it regardless of how it's feeling on any particular day.
Be careful as we could see a retest of the June low in the weeks ahead.
Let's review the charts and indicators.
Amicus Therapeutics and Eiger BioPharmaceuticals set up well for using my covered call strategy.
Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.
VERU's cancer drug Veru-111 was found to also be effective in treating Covid-19 patients in Phase II trials.
JAGX has a drug that is impactful against a key symptom of Covid-19 long-hauler syndrome.